Agilent Technologies has entered into a definitive agreement to acquire privately-held ProZyme, a provider of glycan analysis reagents, kits and standards. This acquisition will expand Agilent’s portfolio of biopharma consumables in the fast-growing glycan market. “Agilent is focused on being a complete workflow solutions provider,” said Mark Doak, president of Agilent’s CrossLab Group. “We have a strong installed base of customers worldwide, and expanding our co...